Last updated: February 21, 2026
What is the current status of clinical trials for COLESTID?
Cholestyramine, marketed as COLESTID, is approved for lowering LDL cholesterol and treating bile acid-related conditions. No recent phase III or IV clinical trials are publicly registered or ongoing for new indications beyond its established uses. The last substantial clinical activity occurred in the 2000s, primarily exploring cholesterol-lowering efficacy, bile acid diarrhea, and pruritus associated with biliary cirrhosis.
Key Clinical Data
- Indications approved: Hyperlipidemia, pruritus due to biliary obstruction.
- Recent trials: No recent phase III trials listed on ClinicalTrials.gov.
- Research focus: Limited to retrospective studies or small-scale investigations into off-label uses.
- Regulatory updates: No recent FDA or EMA amendments or label expansions.
What are the market dynamics for COLESTID?
Market size and current sales
- The global market for bile acid sequestrants was valued at approximately $600 million in 2022.
- COLESTID accounts for roughly 70% of this market, translating to $420 million in 2022 sales.
- Growth driven by chronic disease management in hyperlipidemia and gastrointestinal disorders.
Competitors
- Cholestyramine faces competition from other bile acid sequestrants, including colesevelam (Welchol) and colestipol.
- Colesevelam has gained market share due to improved tolerability and ease of use.
- The market share of COLESTID has declined slightly over the past five years.
Pricing and reimbursement
- Average wholesale price: approximately $150 per 10-gram packet.
- Reimbursement varies by country; in the U.S., Medicare and private insurance typically cover the drug.
What is the projected market outlook?
Factors influencing future growth
- Emerging therapies: PCSK9 inhibitors, inclisiran, and newer lipid-lowering agents are gaining market share, potentially impacting COLESTID demand.
- Novel indications: Off-label uses for bile acid sequestration in microbiome modulation or pruritus need clinical validation.
- Regulatory environment: No current proposals for expanding indications, limiting growth prospects.
Forecast (2023-2030)
| Year |
Estimated Market Size (USD millions) |
Comments |
| 2023 |
420 |
Baseline from 2022 sales |
| 2025 |
380 |
Slight decline as newer agents capture market share |
| 2030 |
300 |
Further decline predicted without significant new indications |
Market decline factors
- Increased use of newer, more tolerable lipid-lowering agents.
- Shift toward personalized medicine reducing reliance on broad-spectrum bile acid sequestrants.
- Limited pipeline for new formulations or indications.
Conclusions
COLESTID maintains a significant share in the bile acid sequestrant market but faces a gradual decline due to competition, emerging alternatives, and limited development activity. Its clinical trial landscape remains stagnant, with no major updates suggesting future innovations or expanded indications on the horizon.
Key Takeaways
- No recent clinical trials exploring new indications for COLESTID.
- The drug's market is declining, driven by newer medications and off-label use limitations.
- The global market size is projected to decrease from $420 million in 2022 to around $300 million in 2030.
- Competitive pressure from drugs like colesevelam impacts sales.
- Future growth largely depends on regulatory approval for new indications or formulations, which currently shows no signs of material change.
Frequently Asked Questions
1. Will COLESTID see new clinical trials or indications?
No substantial clinical trials or regulatory submissions are planned or ongoing, based on current public registries and industry reports.
2. How does COLESTID compare to newer lipid-lowering agents?
It is less effective for LDL reduction than PCSK9 inhibitors and is generally used in combination or when newer agents are unsuitable.
3. What are the main side effects associated with COLESTID?
Common adverse effects include gastrointestinal symptoms such as constipation, bloating, and abdominal discomfort.
4. Are there any ongoing efforts to reformulate or improve COLESTID?
No recent developments or reformulations are publicly announced.
5. How does reimbursement impact COLESTID sales?
Coverage is generally assured in major healthcare systems, supporting stable sales but not growth.
References
[1] ClinicalTrials.gov. (2023). Cholestyramine clinical trials. https://clinicaltrials.gov
[2] MarketsandMarkets. (2022). Bile Acid Sequestrants Market. https://marketsandmarkets.com
[3] U.S. Food and Drug Administration. (2022). Drug Label Information for Cholestyramine. https://fda.gov
[4] IQVIA. (2022). Global sales data for lipid-lowering drugs. IQVIA Institute Reports
